Towards Healthcare
Consumer Genomics Market Size | 24.85% CAGR Growth by 2033

Consumer Genomics Market to Set USD 14.45 Billion by 2033

The report covers Consumer Genomics Market Segment Analysis categorized by application and region. By application includes genetic relatedness, ancestry, lifestyle, wellness & nutrition, diagnostics, sports nutrition & health, reproductive health and personalized medicine & pharmacogenetic testing. Regional includes North America, Europe, Asia Pacific, Latin America and the Middle East and Africa (MEA). The report offers the value (in USD Billion) for the above segments.

The global consumer genomics market size was estimated at US$ 1.57 billion in 2023 and is projected to grow to US$ 14.45 billion by 2033, rising at a compound annual growth rate (CAGR) of 24.85% from 2024 to 2033. The expansion of this market is being driven by an increase in the demand for direct-to-consumer genetic testing in recent times.

Consumer Genomics Market Revenue 2023 - 2033

Unlock Infinite Advantages: Subscribe to Annual Membership

Key Takeaways

  • North America dominated the consumer genomics market with the largest revenue share of 38% in 2023.
  • Asia Pacific is expected to grow at a double-digit CAGR of 25.42% during the forecast period.
  • By application, the genetic relatedness segment has contributed more than 21% of revenue share in 2023.
  • By application, the lifestyle, wellness, & nutrition segment is estimated to grow with the fastest CAGR during the forecast period.

Industry at a Glance

The consumer genomics market consists of two segments: consumer-driven genetic testing, which is genetic testing ordered by a health care provider in response to an informed patient request, and direct-to-consumer applications, which are genetic tests obtained directly from a commercial company without the involvement of a health care provider. Due to the possibility of consumer misinterpretation, conversations on the necessity to demonstrate clinical and analytical validity as well as clinical utility have arisen as consumer genomics has become more and more integrated with clinical applications. Practitioners have faced obstacles in terms of education and training because of clinical preparedness and interest in this information. Concurrently, the consumer genomics market has surfaced as a potentially inventive domain for contemplating health literacy and enlisting individuals in their own health and medical care.

Top Companies in the Consumer Genomics Market

  • Nucleus Genomics
  • Illumina, Inc.
  • SOFiA Genetics
  • Metabolomic Discoveries GmbH
  • Amgen, Inc.
  • MyHeritage Ltd.
  • Xcode Life
  • Positive Biosciences, Ltd
  • Veritas
  • Gene by Gene, Ltd. (FamilyTree DNA)
  • Mapmygenome
  • Diagnomics, Inc.
  • QuickCheck Health
  • SomaLogic, Inc.
  • Helix OpCo LLC
  • Color Health, Inc
  • Futura Genetics
  • Inui Health (formerly Scanadu)
  • Pathway Genomics
  • Ancestry
  • 23andMe, Inc.
  • Myriad Genetics, Inc
  • Toolbox Genomics
  • AgeCurve
  • Biomeb

Recent Development by Nucleus Genomics in the Consumer Genomic Market

Company Name Nucleus Genomics
Headquarters New York, U.S., North America
Recent Development In March 2024, in an effort to provide everyone with the advantages of customized treatment, Nucleus Genomics, a business that specializes in next-generation genetic testing and analysis, announced the introduction of its DNA analysis product. Consumers who have already had microarray genetic testing with other testing businesses can upload their DNA data into Nucleus' platform to learn more about their genetic susceptibility to a variety of illnesses, including breast cancer and type 2 diabetes. By using lifestyle and personal parameters like age, blood pressure, cholesterol, and BMI in its analysis, Nucleus further customizes these risk evaluations.

Recent Development by SOPHiA Genetics in the Consumer Genomics Market

Company Name SOFiA Genetics
Headquarters Switzerland, Europe
Recent Development In May 2024, a leading global provider of data-driven medicine, SOPHiA GENETICS, a cloud-native healthcare technology company, recently revealed that it is joining forces with Microsoft and NVIDIA to combine their technological and genomics expertise to provide healthcare facilities with a streamlined and scalable whole genome sequencing (WGS) analytical solution. It is expected that clients will have access to the solution by the end of 2024. SoPHiA GENETICS's new whole genome sequencing (WGS) application will enable scientists and physicians to quickly obtain fully annotated whole genome insights, enabling them to make data-driven decisions the same day.

Technological Advancements are Driving the Consumer Genomics Market

The most significant technical advancement in the life sciences that has made genomics possible for precision medicine, and more particularly for the life sciences, is high-throughput sequencing (NGS) and its more recent expansion to long-read sequencing. Sequencing has been more accessible due to declining costs, which has had a wider range of effects, including increased application in healthcare. All of this points to new developments in consumer genomics analytic platforms and technology. Helix, an Illumina-backed genomics business with a consumer focus, is one of the recent entries.

Privacy Concerns Restraint the Consumer Genomics Market

The use of genomic testing has moved from being uncommon to commonplace in many therapeutic settings due to outstanding advances in genomics research in recent years. While there are obvious therapeutic benefits to this kind of testing, patients should be aware that there are also new privacy hazards associated with it, including the possibility that their genetic information may be misused. There are still issues with applicants for life, long-term care, and disability insurance being discriminated against based on their genetic information. GINA is not the only law that protects patient privacy; HIPAA also limits the sharing of medical records.

Personalized Genomics is the Future of Consumer Genomics Market

Global healthcare is being revolutionized by personalized genomics, which is the combination of genetic testing and biotechnology. Genetics is a significant factor in human development since it affects a person's qualities, abilities, and general health in a variety of ways. Through genetic profiling analysis, medical interventions and medications can be customized to an individual's specific genetic traits, improving treatment outcomes and decreasing side effects. Consumer genomics acknowledges that genetics and lifestyle have complex interactions that affect health. The ability to customize one's lifestyle and health through access to one's specific genetic information results in observable and quantifiable improvements. Adopting a genome-based lifestyle can have significant effects on a person's health, enhancing their general well-being and quality of life.

Report Highlights

Application Insights

The genetic relatedness segment held the largest share of the consumer genomics market in 2023. Finding missing people, paternity testing, genealogy, and family searches are just a few of the numerous applications that depend on the idea of relatedness. The application of human genetics requires the ability to draw conclusions from genetic data in an ethical manner. Ensuring accurate inference on current genetic relatedness, like family structure, and more distant genetic relatedness, like population structure, is crucial for safeguarding against false correlations in genome-wide and sequencing association studies, for instance.

The last 20 years have seen a rise in the use of genetic testing throughout the world. More than 90% of tests that are sent to GTR are not intended for research but rather for clinical use. In 2012 and 2022, respectively, there were 1081 and 6214 new genetic tests available globally. There were just 607 new genetic tests available in the U.S. in 2012, compared to 3097 in 2022.

Genetic Tests, 2022

The lifestyle, wellness & nutrition segment is estimated to grow with the fastest CAGR in the consumer genomics market during the forecast period. By analyzing your DNA, genetic testing determines your hereditary susceptibility to a range of disorders and characteristics. This can include dietary preferences like a need for antioxidants, sensitivity to gluten, and many other dietary differences linked to health aspects like metabolism, weight gain and loss. A number of these tests claim to provide insights into things like food preferences, fitness, nutrition, hazards related to health, and even genetic differences. People are able to customize anything to fit their own preferences.

Regional Insights

North America dominated the consumer genomics market by 38% in 2023, driven by a number of variables, including a proactive approach to tailored treatment, a high frequency of illnesses connected to lifestyle, and growing consumer awareness. The area has a strong healthcare foundation, which has helped consumer genomics services become widely used. In addition, industry development has been fueled by strategic partnerships between genetic testing businesses and healthcare providers as well as by supportive regulatory environments.

In the U.S., there are key consumer genomics market players, and the country is also dominating in technological advancements. Apart from this, the government of the U.S. continuously provides resources and develops programs and schemes to conduct research and clinical development. The country also demands consumer genomics due to the growing prevalence of lifestyle-related diseases and deaths. These diseases include cardiovascular diseases, type 2 diabetes, stroke and so on.

Deaths Associated with Lifestyle-Related Diseases in the U.S., 2022

Asia Pacific is expected to grow at the fastest rate of 23% during the forecast period. The consumer genomics market is expanding due to a number of factors, including a big and diversified population, increased disposable incomes, and growing knowledge of the advantages of genetic testing. Even though the industry is still in its infancy, rising healthcare infrastructure development and an increase in illnesses linked to a healthy lifestyle in nations like China and India present enormous opportunities for consumer genomics firms to enter this enormously large and unexplored market.

For instance,

  • In March 2024, one of the top personal genomics businesses in India, Xcode Life, announced the release of their brand-new "Genes and Caffeine" test. Since every person has a different connection with coffee, this test has been created with that in mind. It offers insights into how a person's genes affect their body's response to caffeine, delving further into the realm of caffeine than the typical "one-size-fits-all" advice. India's most thorough gene nutrition test, covering almost 50 nutritional factors, is provided by Xcode Life.

Recent Developments in the Consumer Genomics Market

  • In July 2024, the inventor of innovative and extremely distinctive single-cell technology, Fluent BioSciences, was bought by Illumina, Inc., a leading company in the world of array-based technologies and DNA sequencing as today. The acquisition of Fluent BioSciences by Illumina will expand our multi-omics growth plan and offer customers substantial and novel capabilities in a critical growth area.
  • In April 2023, the purpose of Function Oncology, a precision medicine startup, is to create a personalized functional genomics platform driven by CRISPR that will transform the landscape of targeted cancer treatment in the future. The San Diego-based firm is dedicated to developing the next generation of targeted cancer medicines by evaluating gene function at the individual patient level, as opposed to depending on conventional gene sequencing.
  • In June 2023, Nutrigenomics is the latest venture of Xcode Life. The business has introduced a thorough Gene Nutrition test that addresses about 50 facets of diet. The examination examines how the macronutrients (carbs, protein, and fats) are broken down based on genotype, the likelihood of vitamin and mineral deficiencies, eating habits, managing weight in relation to nutrition, taste preferences, diet responses, and food sensitivity. Xcode investigates the relationship between food and how it impacts gene expression and health, as well as the influence of genes on an individual's body's reaction to food, as part of its focus on nutrigenomics. It adds credibility and personalization to dietary recommendations by considering each person's own genetic composition.
  • In October 2022, ChemoCentryx, Inc., a biopharmaceutical company focused on oral therapies for the treatment of cancer, inflammatory illnesses, and autoimmune diseases, was acquired by Amgen for $52 per share in cash, which amounted to an estimated $3.7 billion in total merger consideration. The acquisition was successfully completed, as previously announced.

Segments Covered in the Report

By Application

  • Genetic Relatedness
  • Ancestry
  • Lifestyle, Wellness & Nutrition
  • Diagnostics
  • Sports Nutrition & Health
  • Reproductive Health
  • Personalized Medicine & Pharmacogenetic Testing

By Region

  • North America 
    • U.S.
    • Canada
  • Europe 
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Sweden
    • Denmark
    • Norway
  • Asia Pacific 
    • China
    • Japan
    • India
    • South Korea
    • Thailand
  • Latin America 
    • Brazil
    • Mexico
    • Argentina
  • Middle East and Africa (MEA) 
    • South Africa
    • UAE
    • Saudi Arabia
    • Kuwait

Complementary Report

The Power of AI in Genomics: Transforming into Advancing Personalized Medicine

Artificial intelligence (AI) has significantly transformed the field of genomics by merging advanced algorithms with extensive genomic data, driving major advancements in personalized medicine. In research, AI analyzes large datasets to identify patterns and relationships between genes and diseases, leading to the discovery of new biomarkers and therapeutic targets. In clinical diagnostics, AI enhances the interpretation of genomic data, improving disease diagnosis and risk assessment while enabling personalized treatment plans. This progress in AI-powered genomics also propels precision medicine, allowing healthcare providers to make more informed decisions on disease prevention, diagnosis, and treatment based on an individual's unique genetic profile, ultimately enhancing patient outcomes.

  • The global AI in genomics market size valued at USD 397.64 million in 2022 is projected to grow at a CAGR of 23.6% from 2023 to 2032, reaching an estimated USD 7,365.59 million by 2032. This growth is driven by increasing cross-industry collaborations and heightened R&D efforts. North America accounted for a 29.25% market share in 2023.
  • Insight Code: 5184
  • No. of Pages: 150+
  • Format: PDF/PPT/Excel
  • Published: July 2024
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2022
  • Base Year: 2023
  • Estimated Years: 2024-2033

Meet the Team

Deepa Pandey is a healthcare market research expert with 2+ years of experience, specializing in analyzing market trends, regulatory impacts, and emerging opportunities to guide strategic decision-making in the healthcare sector.

Learn more about Deepa Pandey

Aditi Shivarkar, with 14+ years of healthcare market research experience, ensures the accuracy, clarity, and relevance of reports. Her expertise helps businesses make informed decisions and stay competitive in healthcare sectors.

Learn more about Aditi Shivarkar

Related Reports

FAQ's

DTC tests are frequently used by people to learn about their history, uncover personal characteristics like a dislike for cilantro, and obtain health-related information (such as illness risk prediction).

The cost may be as little as $100 or as much as hundreds of dollars. The cost of the test is frequently not reimbursed by health insurance companies because DTC-GT results are generally not regarded as diagnostic.

The U.S. Department of State, National Institutes of Health, NCBI. WHO. Centers for Disease Control and Prevention.